

Looking for dedicated education on drug development in oncology?

Oncology Drug Development in Practice (ODDP) is an educational program that teaches knowledge and skills needed by professionals in oncology drug development in the corporate or the academic setting.

Fully dedicated
to oncology drug
development

Targeting in
particular
professionals
who are new in
oncology

Covers the
complete drug
development
process

Includes
education on
essentials of
oncology

High level of
participant
satisfaction over
15 years' history

Training Course **Oncology Drug
Development in Practice**

● www.congressbydesign.com/ODDP
●
●
●

Amsterdam, The Netherlands
November 28-30, 2018

Target audience

ODDP 2018 is a 3-day educational program that serves several target audiences:


- Anyone looking for a solid introduction into the essentials of oncology will benefit from participating in part A;
- Drug development professionals in industry and academia (*) wishing to acquire or expand knowledge of oncology drug development will benefit from participating in parts A and B combined or part B only, depending on their starting level of oncology knowledge.

Parts A (day 1) and B (days 2 and 3) may be booked separately or combined. For successful participation in either part, an understanding of the basic principles of biology and medicine at the graduate level is recommended. Pre-reading materials will be provided to registered participants well before the start of the course

(*) Reduced tuition for participants employed by not-for-profit entities.

Why participate in ODDP 2018?

- Exclusively focused on oncology
- Impressive 15-year track record
- High participant satisfaction over the years
- Particularly useful for those entering oncology drug development
- No upfront oncology knowledge required for successful participation
- Covers the complete anticancer drug development process
- Provides stand-alone introduction into oncology for a broad audience





Education offered

Part A (day 1) offers education on tumor biology, pathology, and various domains of cancer patient management in sessions dedicated to:

- Cancer and cancer therapeutics
- Carcinogenesis & tumor cell biology
- Oncopathology: Diagnosing cancer
- Essentials of medical oncology
- Essentials of hemato-oncology
- Essentials of cancer immunotherapy

Part B (day 2 and 3) offers education on anticancer drug development, with a focus on the situation in Europe and a number of associated areas in sessions dedicated to:

- Drug discovery and preclinical drug testing
- Preclinical toxicology of anticancer agents
- Phase 1 clinical studies with single agents
- Phase 1 clinical studies with combinations of agents
- Full clinical development of cancer therapeutics
- Post-registration drug development in oncology
- Biomarkers in oncology drug development
- Development of companion diagnostics for cancer therapeutics
- The regulatory environment for anti-cancer drug development
- Biostatistical considerations in oncology clinical trials



Faculty

Education will be presented by experts from leading academic research institutes and oncology-orientated drug companies, all having ample expertise and hands-on experience in cancer research, clinical oncology, and/or anticancer drug development.

Confirmed faculty as per June 1, 2018:

- **Rob Berg**, Executive Medical Director, Syneos Health, Amsterdam, NL
- **Lucinda Billingham**, Institute of Cancer and Genomic Sciences, Birmingham, United Kingdom
- **Christian Blank**, Medical Oncologist, Netherlands Cancer Institute, Amsterdam, NL
- **Paul van Diest**, Professor of Pathology, University Medical Center, Utrecht, NL
- **Ferry Eskens**, Medical Oncologist, Erasmus MC, Rotterdam, NL
- **Adriaan Fruijt**, Director, Regulatory Affairs, CATS Consultants, Dietmannsried, Germany
- **Alain van Gool**, Professor Personalized Healthcare, Radboud University Medical Center, Nijmegen, NL
- **Eric Hoedemaker**, Medical Director Novartis Oncology, NL
- **Michel Janicot**, Founder & CEO, JMi ONConsulting, Brussels, Belgium
- **Jos Jonkers**, Professor of Molecular Experimental Oncogenetics and Cancer Therapeutics, Netherlands Cancer Institute, Amsterdam, NL
- **Martina Kaufmann**, Martina Kaufmann Strategic Consulting, Muellheim, Germany
- **Marie José Kersten**, Hematologist, Academic Medical Center, Amsterdam, NL
- **Anna Minchom**, Consultant Medical Oncologist, Royal Marsden Hospital and The Institute of Cancer Research, UK
- **Eric van der Putten**, Partner, Aglaia Biomedical Ventures, Bilthoven, NL
- **Benno Rattel**, Executive Director, Amgen, Munich, Germany
- **Jan Vermorken**, Emeritus-Professor of Medical Oncologist, Antwerp University Hospital, Edegem, Belgium

Venue

The course will be held at Mercure Hotel Amsterdam City, only 15 minutes from Amsterdam Schiphol Airport by taxi. Schiphol has frequent daily connections with most European capitals and many other destinations. The venue can also be reached conveniently by high-speed trains from Paris, London, Brussels, and other European cities, and by car via motorway A2.

Hotel accommodation

The course venue offers participants convenient hotel accommodation at the attractive rate of EUR 140 per night, including breakfast, excluding 5% city tax.

Tuition and registration

Category	Part A and B	Part A only	Part B only
Non-profit	EUR 1,950	EUR 725	EUR 1,325
Corporate	EUR 2,600	EUR 950	EUR 1,750

All fees are exclusive of VAT and do not include hotel accommodation and dinners. Coffee, tea, and lunches are included.

To register, visit www.congressbydesign.com/oddp. A maximum of 30 participants will be accepted for either part of the course. Applications will be accepted in the order in which they are received.

Sponsor acknowledgements



ODDP series main sponsor

Syneos Health is a therapeutically focused clinical research organization with a high-performance reputation for conducting global clinical development programs of the highest integrity. Pharmaceutical and biotechnology companies look to us for a complete range of customized Phase I to IV programs in all therapeutic areas and patient populations. For more information: syneoshealth.com.



Co-sponsor ODDP 2018

Aglaia Biomedical Ventures is founded on the principle that the willingness to take risks on the very early stage ventures of today results in opportunities that may grow into the winning companies of tomorrow. Aglaia invests in companies that are spun-off from academic institutes, in existing early stage companies, as well as in single projects in which promising anticancer compounds are developed, all with the aim of improving treatment of cancer patients. More information: aglaia-biomedical.com.

Course management



CONGRESS BY DESIGN

P.O. Box 77
3480 DB Harmelen
The Netherlands
Tel. +31 (0)88 089 8101
oddp@congressbydesign.com
www.congressbydesign.com/ODDP